DNA Chip Based Prognosis of Lung Cancer

Medical Prognosis Institute

Status: Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Study type: Observational

Funder types: Industry

Identifiers

NCT00973427

WIRB Protocol #20080904

MPI-1001

H-B-2007-099

Details and patient eligibility

About

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Enrollment: 144 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. A histological diagnosis of primary NSCLC stage Ia
2. Surgical removal of the tumor
3. Age between 18 and 75 years
4. Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
2. Adjuvant treatment with chemotherapy.
3. Prior history of cancer in the past 5 years or breast cancer at any time.
4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.